Skip to main content

Iptacopan Dosage

Medically reviewed by Drugs.com. Last updated on Jan 29, 2024.

Applies to the following strengths: 200 mg

Usual Adult Dose for Paroxysmal Nocturnal Hemoglobinuria

200 mg orally twice a day

Comments:


Use: For the treatment of patients with PNH

Usual Adult Dose for Primary Immunoglobulin A Nephropathy

200 mg orally twice a day

Comments:


Use: To reduce proteinuria in patients with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio at least 1.5 g/g

Renal Dose Adjustments

Renal dysfunction: Data not available

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended
Severe liver dysfunction (Child-Pugh C): Not recommended

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for iptacopan. It includes elements to assure safe use and an implementation system. For additional information: www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNING:


CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

General:

Monitoring:

Patient advice:

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.